Free Trial

CRISPR Therapeutics (CRSP) SEC Filings & 10K Form

CRISPR Therapeutics logo
$47.91 -2.52 (-5.00%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$47.75 -0.16 (-0.33%)
As of 02/21/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent CRISPR Therapeutics SEC Filings

DateFilerForm TypeView
02/21/2025
4:35 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
4:35 PM
CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
4:35 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
4:35 PM
Bruno Julianne (Reporting)
CRISPR Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
10:23 AM
ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
Form SCHEDULE 13G/A
01/10/2025
8:23 PM
ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
Form SCHEDULE 13G/A
12/27/2024
4:35 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2024
12:34 PM
ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
Form SC 13G/A
11/13/2024
4:35 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2024
8:05 AM
CRISPR Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2024
8:10 AM
CRISPR Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/18/2024
4:35 PM
CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
4:35 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
4:35 PM
CRISPR Therapeutics (Issuer)
Patel Naimish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
4:35 PM
Bruno Julianne (Reporting)
CRISPR Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
4:35 PM
CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
5:00 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
5:00 PM
CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2024
5:45 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2024
4:22 PM
CRISPR Therapeutics (Filer)
Form S-3ASR
06/24/2024
4:35 PM
Bruno Julianne (Reporting)
CRISPR Therapeutics (Issuer)
CRISPR Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
7:06 AM
CRISPR Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/31/2024
3:50 PM
Behbahani Ali (Reporting)
CRISPR Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/31/2024
3:50 PM
CRISPR Therapeutics (Issuer)
George Simeon (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2024
7:14 AM
CRISPR Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
3:15 PM
CRISPR Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2024
4:45 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2024
3:24 PM
CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/10/2024
10:58 AM
Capital International Investors (Filed by)
CRISPR Therapeutics (Subject)
Form SC 13G/A
04/09/2024
3:42 PM
CRISPR Therapeutics (Filer)
Form DEF 14A
04/09/2024
3:43 PM
CRISPR Therapeutics (Filer)
Form DEFA14A
04/09/2024
3:47 PM
CRISPR Therapeutics (Filer)
Form ARS
03/27/2024
3:30 PM
CRISPR Therapeutics (Filer)
Form PRE 14A
03/27/2024
3:30 PM
CRISPR Therapeutics (Filer)
Form PRE 14A
03/22/2024
4:45 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/22/2024
4:45 PM
CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/22/2024
4:45 PM
CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/22/2024
3:02 PM
CRISPR Therapeutics (Subject)
Morrow Phuong Khanh (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/18/2024
4:45 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2024
4:45 PM
CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:43 PM
CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Warning: Elon’s $20k Robot Might Replace Your Nanny (Ad)

Tesla’s Robot Revolution Has Begun It’s official… Tesla’s robot revolution is underway… By the end of this year, Tesla plans to produce 600 new “Tesla Bots” per week… Tech insiders believe this could be the company’s next core driver of explosive growth. Some even believe it could be the catalyst that would push shares above the $1,000 mark. That’s essentially a 100% increase from today’s price…

03/12/2024
4:45 PM
CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
4:45 PM
CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2024
5:39 PM
CRISPR Therapeutics (Issuer)
George Simeon (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners